Log in

PHRM Pharmhold AD BSESOF · Bulgaria

Pharmhold AD (PHRM) news

Pharmhold AD is a public biotech or pharmaceutical company listed on BSESOF under the ticker PHRM, recorded under Bulgaria. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Pharmhold AD news

We have not published a story on Pharmhold AD yet. When there is news, it will appear here.

Questions about Pharmhold AD

What is the ticker symbol of Pharmhold AD?

Pharmhold AD trades under the ticker PHRM on BSESOF.

Where is Pharmhold AD listed?

Pharmhold AD is listed on BSESOF.

Which country or territory is Pharmhold AD listed under?

Our directory records Pharmhold AD under Bulgaria.

What does Pharmhold AD do?

Our directory classifies Pharmhold AD as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Pharmhold AD?

The ISIN recorded for Pharmhold AD is BG1100002150.

Does aibio.space cover Pharmhold AD?

aibio.space lists Pharmhold AD among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Pharmhold AD?

Companies in our directory listed in the same country and business area as Pharmhold AD: Sopharma AD, Tchaikapharma High Quality Medicines.

Investor discussion: Pharmhold AD

Members talk about Pharmhold AD (PHRM). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Press releases

Headlines of Pharmhold AD's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. Newsfile

    PharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency

Listing details

Pharmhold AD is a public biotech or pharmaceutical company listed on BSESOF under the ticker PHRM, recorded under Bulgaria. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Pharmhold AD
Ticker
PHRM
Listing
BSESOF
Country or territory
Bulgaria
Business scope
Pharmaceuticals: Major
ISIN
BG1100002150
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.